{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:46:47Z","timestamp":1792802807784,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006316","name":"Alliance for Clinical Trials in Oncology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1 CA189823"],"award-info":[{"award-number":["UG1 CA189823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1 CA232760"],"award-info":[{"award-number":["UG1 CA232760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["A151930"],"award-info":[{"award-number":["A151930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jgo.2025.102185","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:03:40Z","timestamp":1736773420000},"page":"102185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303"],"prefix":"10.1016","volume":"16","author":[{"given":"Vicki A.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Bobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Satele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2025.102185_bb0005","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V116.21.589.589","article-title":"R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients: long-term follow-up of intergroup E4494\/C9793","volume":"116","author":"Morrison","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2025.102185_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2025.102185_bb0020","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2025.102185_bb0025","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2025.102185_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"German high-grade non-Hodgkin lymphoma study group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2025.102185_bb0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2025.102185_bb0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9880","key":"10.1016\/j.jgo.2025.102185_bb0045","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jgo.2025.102185_bb0050","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"issue":"35","key":"10.1016\/j.jgo.2025.102185_bb0055","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","volume":"32","author":"Molina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.jgo.2025.102185_bb0060","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/10428194.2015.1045898","article-title":"A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma","volume":"57","author":"Hainsworth","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2025.102185_bb0075","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large N-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2025.102185_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.57","article-title":"NCCTG N1085 (Alliance): high rate of event-free survival at 24 months with everolimus + R-CHOP for untreated diffuse large B-cell lymphoma: updated results from lymphoma: updated results from NCCTG N1085 (Alliance)","volume":"7","author":"Witzig","year":"2017","journal-title":"Blood Cancer J"},{"issue":"31","key":"10.1016\/j.jgo.2025.102185_bb0085","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0090","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2025.102185_bb0095","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0100","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","volume":"5","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2016.255","article-title":"A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high\/high-intermediate risk diffuse large B-cell lymphoma","volume":"31","author":"Reddy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2025.102185_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial","volume":"171","author":"Witzens-Harig","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2025.102185_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzuab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2025.102185_bb0120","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"7","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0125","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1002\/sim.2864","article-title":"Analyzing survival curves at a fixed point in time","volume":"26","author":"Klein","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.jgo.2025.102185_bb0130","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","article-title":"Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793, ECOG-SWOG 4494)","volume":"58","author":"Morrison","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2025.102185_bb0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jgo.2018.03.018","article-title":"Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (Alliance A151611)","volume":"9","author":"Tallarico","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2025.102185_bb0140","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jgo.2020.02.002","article-title":"Practice patterns in older patients with diffuse large B-cell lymphoma: a medicare analysis, 2007-2015","volume":"11","author":"Levin","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2025.102185_bb0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12765","article-title":"Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study","volume":"165","author":"Wieringa","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:43:11Z","timestamp":1741149791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1879406825000013"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102185","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102185"}}